Mark Isalan

USPTO Granted Patents = 12 (Patent Applications = 4)

CIPO Patents = 1

EPO Patents = 3 (Patent Applications = 5)

Average Co-Inventor Count = 2.7

ph-index = 6

Forward Citations = 345(Granted Patents)

Company Filing History:

Gendaq Limited, C/o Brobeck Hale and Dorr

patent

1 out of 141

Imperial College Innovations Limited

patents

Years Active: 2002-2025

Loading Chart...

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12397065 - Nucleic acids, peptides and methods (2025-08-26),

2. 8618024 - Nucleic acid binding polypeptide library (2013-12-31),

3. 8617807 - Nucleic acid binding proteins (2013-12-31),

4. 7947469 - Modulation of HIV infection (2011-05-24),

5. 7759059 - Nucleic acid binding proteins (2010-07-20),

6. 7700523 - Nucleic acid binding polypeptide library (2010-04-20),

7. 7241574 - Nucleic acid binding proteins (2007-07-10),

8. 7241573 - Nucleic acid binding proteins (2007-07-10),

9. 6977154 - Nucleic acid binding proteins (2005-12-20),

10. 6866997 - Nucleic acid binding proteins (2005-03-15),

11. 6746838 - Nucleic acid binding proteins (2004-06-08),

12. 6492117 - Zinc finger polypeptides capable of binding DNA quadruplexes (2002-12-10),

Title: Mark Isalan: Innovator in Nucleic Acid and Peptide Technologies

Introduction

Mark Isalan is a prominent inventor based in London, GB. He has made significant contributions to the fields of nucleic acids and peptides, particularly in the context of treating polyglutamine diseases such as Huntington's disease. With a total of 12 patents to his name, Isalan's work is at the forefront of medical innovation.

Latest Patents

Among his latest patents, Isalan has developed novel nucleic acid molecules that encode unique polypeptides aimed at treating polyglutamine diseases. These polypeptides exhibit reduced immunotoxicity in vivo, making them suitable for sustained expression in medical therapies. Additionally, he has disclosed methods for treating polyglutamine diseases and the use of these nucleic acids and polypeptides in gene therapy. Another significant patent involves a zinc finger polypeptide library, which includes polypeptides with multiple zinc fingers that have been partially randomized, allowing for the assembly of multifinger zinc finger polypeptides after selection.

Career Highlights

Mark Isalan has worked with Gendaq Limited, where he contributed to groundbreaking research and development in his field. His expertise has been instrumental in advancing the understanding and treatment of complex diseases.

Collaborations

Isalan has collaborated with notable individuals in the scientific community, including Yen Choo and Aaron Klug. These partnerships have further enriched his research and innovation efforts.

Conclusion

Mark Isalan's contributions to the fields of nucleic acids and peptides are paving the way for new treatments for polyglutamine diseases. His innovative patents and collaborations highlight his commitment to advancing medical science.

This text is generated by artificial intelligence and may not be accurate.